Denali Therapeutics Inc. 8-K

What Happened
Denali Therapeutics Inc. (DNLI) announced on March 25, 2026, via a Form 8-K (Regulation FD disclosure), that the U.S. Food and Drug Administration approved AVLAYAH (tividenofusp alfa) for the treatment of neurologic manifestations in patients with Hunter syndrome (MPS II). The approval applies when treatment is initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. The company attached a press release as Exhibit 99.1 to the filing.

Key Details

• FDA approval announced March 25, 2026 for AVLAYAH (tividenofusp alfa).
• Indication: neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients ≥5 kg when started before advanced neurologic impairment.
• Company disclosed the news under Item 7.01 (Regulation FD); press release included as Exhibit 99.1.
• Filing notes (Item 9.01) that the press release/exhibit is furnished, not “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters
This FDA approval is a regulatory milestone that allows Denali to market AVLAYAH in the U.S. for a defined pediatric Hunter syndrome population, moving the program from clinical development toward commercialization. For investors, the approval could affect Denali’s near- and mid-term commercial prospects and warrants watching upcoming details on launch timing, labeling, pricing, reimbursement, and any company guidance or partnering plans.